30 year old primary inferiority with Hyperthyroidism was on 10mg neomercazole since 1 year stopped since 5 days should she continue the same?
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Now I have comprehensive information. Let me synthesize the answer based on the lab report and clinical context.
Clinical Assessment — Mrs. Pallavi, 27F | Primary Infertility + Hyperthyroidism
Lab Report Interpretation (07/04/2026)
| Test | Result | Reference Range | Interpretation |
|---|---|---|---|
| T3 Total | 1.22 ng/mL | 0.35–1.93 | Normal |
| T4 Total | 5.85 µg/dL | 5.48–14.28 | Low-normal |
| TSH | 4.649 mIU/mL | 0.34–5.2 | Normal (upper limit) |
After 1 year of Neomercazole (carbimazole) 10 mg, her thyroid function is now within normal range — she has achieved biochemical euthyroidism.
Should She Continue the Same Dose?
No — the dose needs to be reassessed, not simply continued or stopped abruptly.
Here is the rationale:
1. She Is Now Euthyroid
Her TSH of 4.649 is at the upper end of normal. Combined with low-normal T4, this suggests she may be slightly over-treated or at the edge of drug-induced hypothyroidism. This is exactly the scenario where:
- The maintenance dose should be tapered down (e.g., to 5 mg/day or alternate days), not maintained at 10 mg.
- Continuing full 10 mg when euthyroid risks swinging her into hypothyroidism, which would worsen infertility further.
"The usual daily maintenance doses of antithyroid drugs in the titration regimen are 2.5–10 mg of carbimazole or methimazole" — Harrison's Principles of Internal Medicine, 22E
2. She Has Primary Infertility — Thyroid Correction is Critical
Hyperthyroidism causes infertility through anovulation, menstrual irregularities, and increased sex hormone-binding globulin. Achieving stable euthyroidism is essential for conception. Hypothyroidism (from over-treatment) is equally harmful to fertility.
3. She Stopped 5 Days Ago — Risk of Relapse
Stopping carbimazole abruptly after 1 year carries a real risk of relapse of hyperthyroidism. The recommended treatment duration for Graves' disease is 12–18 months to maximize remission rates (30–60%).
"Maximum remission rates (30–60%) are achieved by 12–18 months for the titration regimen" — Harrison's, 22E
"All patients should be followed closely for relapse during the first year after treatment and at least annually thereafter." — Harrison's, 22E
4. Can Treatment Be Stopped if Near the 12-Month Mark?
Possibly — if she has completed ~12 months of therapy, her TRAb (TSH receptor antibodies) status should be checked:
- TRAb negative → Higher chance of sustained remission (~73%) → Can cautiously stop with close monitoring
- TRAb positive → High relapse risk → Continue treatment
Recommended Plan
| Step | Action |
|---|---|
| Restart carbimazole | Resume at a reduced dose (5 mg/day), not 10 mg, since she is euthyroid |
| Check TRAb | Determines relapse risk and whether drug can be safely stopped |
| Monitor TFTs | Repeat T3, T4, TSH in 4–6 weeks after restarting |
| Infertility workup | Proceed with fertility evaluation now that she is euthyroid — refer gynecologist/reproductive endocrinologist |
| Do NOT leave untreated | Stopping abruptly without confirming remission risks hyperthyroid relapse, which will further impede conception |
"Thyroid function tests and clinical manifestations are reviewed 4–6 weeks after starting treatment, and the dose is titrated based on unbound T4 levels." — Harrison's, 22E
Summary
She should not simply continue the same 10 mg dose, nor should she remain off the drug without TRAb confirmation. The most appropriate step is to restart at a lower dose (5 mg), check TRAb to guide duration of therapy, and monitor TFTs every 4–6 weeks. Once stable euthyroidism is confirmed and TRAb is negative, a supervised trial of discontinuation can be considered — at which point fertility treatment can proceed actively.
This is a shared conversation. Sign in to Orris to start your own chat.